This week the broader market had a significant rebound from the previous week’s performance, the NASDAQ Composite up 4.3% for the year. Both Biotech composite indices were also in the black, though not quite as strongly as the overall market.
In terms of individual issues, CDTX and INZY turned in almost identical performance for the week to take the top spots. A CDTX press release on Wednesday announced that their treatment for invasive yeast infections had been recommended for approval by the advisory committee’s review of phase 2 and phase 3 studies indicating improved performance over the current standard of care treatment. It was not traded on Tuesday, and most of the gain for the week was at the end of Wednesday. INZY had no particular reported reason to explain a significant bump from $1.75 at the close on Wednesday to $2.38 on Friday, with most of the trading being just as the market opened on Friday.
The top YTD performing stock, JSPR, was this week’s top loser, in the red by -39% of its initial price, but given its quadrupling during the first three weeks of the year, that means that it was only a 10% drop in its current price. This was in response to their pricing of a 69 million share public offering (roughly 1.7 times the current number of outstanding shares) at $1.50 a share, a steal for the underwriters given that it closed this week at 1.74. The gross proceeds of this sale, $103 Million, represents a huge influx of cash, given the current market cap of $70 million. Thinking of this as the inverse of a stock buy back, made when a company thinks it is currently undervalued, the interpretation might be that the company is taking advantage of the current premium price the shares are commanding. (And all that cash will probably be useful as well.)
When we look at the contest portfolios, the average ($3.7k) and median ($3.3k) performance for the week beat both biotech composites, though still under the NASDAQ composite’s performance ($4.6k for a $100k portfolio entirely invested in the NASDAQ at the start of the year). On a YTD basis both the average and median portfolio performance (19% and 15%) outperformed even the NASDAQ composite, up 11% for the year.
For the individual portfolios, all but two were in the black for the week. Given BLADERUNNER’s strong exposure to JSPR, responsible for their first place position YTD, their loss of -$2.9k in value for the week might be expected. Even so, BLADERUNNER continues his strong hold on the top YTD performance spot, though the gap between them and second place DEW DILIGENCE has narrowed by $3.9k to a separation of $46k. JACK HARTMEN, RAJU_BIJLEE, and ERIKOTTO had the number 1, 2, and 3 performing portfolios for the week, which was enough to land them in the 3rd, 4th, and 5th spot YTD. Only $5.8k separate 3rd place JACK HARTMEN from 2nd place DEW DILLIGENCE.
This is the first time this year that BLADERUNNER didn’t claim the top spot both for the weekly and YTD performance. Looking at their portfolio makeup, their initial $20k stake in JSPR (with an ROI of 260%!) still dominates the portfolio, even after this week’s dip, representing 41% of the portfolios current value. But all of their picks are doing well, notwithstanding losses in three of them this week. Every one of their stocks are in the black for the year, and even the worst performer, ENTA, has an ROI of 12% so far this year, and BLADRUNNER only had a 5% initial position in it.
In contrast JACK HARTMAN’s portfolio is less dominated (only 13% of the current portfolio value) by their top performing choice, STTK (+61% ROI). Their position as the top performer for the week owes a lot to his choices of STTK coming in 4th and IOVA in 6th in this week’s performance. None of their picks were in the red for this week, although two are underwater YTD. His worst performer YTD, PDSB, is the fourth worst performing stock, -28% for the year, but its only one of his ten choices.
Report Time Ranges
|
|
|
|
|
|
From
|
To
|
|
|
|
|
|
|
|
|
Recent
|
1/20/23
|
1/27/23
|
|
|
|
|
|
|
|
|
YTD
|
12/31/2022
|
|
|
|
|
Index Portfolios’ Performance
|
|
|
|
|
Symbol
|
Recent P/L
|
Recent %
|
YTD P/L
|
|
|
|
|
|
|
|
|
^IXIC
|
$4,598.25
|
4.3%
|
$11,037.42
|
|
|
|
|
|
|
|
|
^NBI
|
$1,162.14
|
1.1%
|
$3,901.42
|
|
|
|
|
|
|
|
|
^SPSIBI
|
$2,917.01
|
2.8%
|
$7,031.68
|
|
|
|
|
Share Performance
|
Recent Performance
|
YTD Performance
|
|
Top Five
|
|
Bottom Five
|
|
Top Five
|
|
Bottom 5
|
Symbol
|
P/L / Initial Price
|
Symbol
|
P/L / Initial Price
|
Symbol
|
YTD P/L / Initial Price
|
Symbol
|
YTD P/L/ Initial Price
|
CDTX
|
56.4%
|
JSPR
|
-39.3%
|
JSPR
|
260.2%
|
BCAB
|
-55.4%
|
INZY
|
55.2%
|
AVTX
|
-17.9%
|
INZY
|
126.7%
|
GRPH
|
-41.6%
|
ATRA
|
42.1%
|
ALGS
|
-17.8%
|
ALGS
|
98.3%
|
FATE
|
-41.3%
|
STTK
|
37.4%
|
SCLP.L
|
-17.7%
|
RVNC
|
79.5%
|
PDSB
|
-28.0%
|
PHAT
|
33.4%
|
MODD
|
-16.3%
|
MBIO
|
77.2%
|
VOR
|
-22.1%
|
Average and Median Portfolio Performance
|
|
Recent P/L
|
|
|
|
YTD P/L
|
|
|
|
Avg.
|
Median
|
|
|
|
Avg
|
Median
|
|
|
|
$3,658.03
|
$3,264.96
|
A.J. MULLEN
|
|
$19,130.89
|
$15,090.43
|
TECHNETIUM
|
Top Seven Portfolio Performances
|
Top Recent Performers
|
Top YTD Performers
|
Contestant (Prev. Rank)
|
Recent P/L
|
P/L vs. ^SPSIBI
|
YTD P/L (Rank)
|
Contestant (Prev. Rank)
|
YTD P/L
|
vs. Top Portfolio
|
P/L vs. ^SPSIBI
|
Rec. P/L (Rank)
|
1 - JACK HARTMANN (12)
|
$12,178.77
|
$9,261.77
|
$25,678.07 (3)
|
1 - BLADERUNNER (1)
|
$77,171.28
|
——
|
$70,139.61
|
-$2,867.94 (15)
|
2 - RAJU_BIJLEE (3)
|
$10,363.43
|
$7,446.42
|
$23,737.41 (4)
|
2 - DEW DILIGENCE (2)
|
$31,389.78
|
$45,781.50
|
$24,358.11
|
$963.81 (12)
|
3 - ERIKOTTO (11)
|
$7,224.11
|
$4,307.10
|
$20,916.75 (5)
|
3 - JACK HARTMANN (6)
|
$25,678.07
|
$51,493.21
|
$18,646.40
|
$12,178.77 (1)
|
4 - RKRW (5)
|
$5,364.18
|
$2,447.18
|
$14,872.96 (9)
|
4 - RAJU_BIJLEE (7)
|
$23,737.41
|
$53,433.88
|
$16,705.73
|
$10,363.43 (2)
|
5 - ARTHUR RADLEY (7)
|
$4,086.59
|
$1,169.58
|
$15,744.90 (7)
|
5 - ERIKOTTO (4)
|
$20,916.75
|
$56,254.54
|
$13,885.07
|
$7,224.11 (3)
|
6 - GENEGURU (13)
|
$3,968.97
|
$1,051.96
|
-$427.96 (15)
|
6 - ALONER (3)
|
$20,778.32
|
$56,392.97
|
$13,746.64
|
$2,850.82 (9)
|
7 - STEVE LOKNESS (15)
|
$3,310.81
|
$393.80
|
$10,359.23 (12)
|
7 - ARTHUR RADLEY (8)
|
$15,744.90
|
$61,426.39
|
$8,713.22
|
$4,086.59 (5)
|
Top Portfolios’ Contents
|
Top Recent Performance Portfolio (JACK HARTMANN)
|
Top YTD Performance Portfolio (BLADERUNNER)
|
Symbol (Rank)
|
Current Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
Symbol (Rank)
|
Initial Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
AMRN
|
10.0%
|
12.2% | 52.9%
|
$5,289.26
|
$247.93
|
6.5%
|
CRDF
|
20.0%
|
14.0% | 24.3%
|
$4,857.14
|
-$428.57
|
4.0%
|
GMDA
|
10.0%
|
10.0% | 25.6%
|
$2,558.14
|
$620.16
|
8.0%
|
CRIS
|
15.0%
|
12.0% | 41.7%
|
$6,259.09
|
$2,168.18
|
4.7%
|
HUMA
|
10.0%
|
10.5% | 31.8%
|
$3,175.36
|
$1,279.62
|
7.6%
|
ENTA
|
5.0%
|
3.2% | 11.8%
|
$591.14
|
$187.02
|
17.9%
|
ICPT
|
10.0%
|
11.8% | 48.7%
|
$4,874.70
|
$1,843.17
|
6.7%
|
IOVA
|
10.0%
|
7.2% | 27.7%
|
$2,769.95
|
$2,957.75
|
7.8%
|
IOVA
|
10.0%
|
10.2% | 27.7%
|
$2,769.95
|
$2,957.75
|
7.8%
|
JSPR
|
20.0%
|
40.7% | 260.2%
|
$52,049.69
|
-$7,867.49
|
1.4%
|
LYEL
|
10.0%
|
7.7% | -3.7%
|
-$374.64
|
$1,008.65
|
10.4%
|
MBIO
|
10.0%
|
10.0% | 77.2%
|
$7,721.52
|
$30.38
|
5.6%
|
NGM
|
10.0%
|
8.1% | 1.4%
|
$139.44
|
$0.00
|
9.9%
|
MGTA
|
5.0%
|
3.3% | 17.0%
|
$849.37
|
-$606.33
|
17.1%
|
PDSB
|
10.0%
|
5.7% | -28.0%
|
-$2,795.45
|
$234.85
|
13.9%
|
MRSN
|
15.0%
|
9.6% | 13.8%
|
$2,073.38
|
$691.13
|
5.9%
|
RBOT
|
10.0%
|
11.1% | 39.1%
|
$3,910.89
|
$247.52
|
7.2%
|
|
|
|
|
|
|
STTK
|
10.0%
|
12.8% | 61.3%
|
$6,130.43
|
$3,739.13
|
6.2%
|
|
|
|
|
|
|
|
